OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer
Rui Zhang, Ge Cheng, Shengnan Liu, et al.
Journal of Materials Chemistry B (2021) Vol. 9, Iss. 42, pp. 8809-8822
Closed Access | Times Cited: 7
Rui Zhang, Ge Cheng, Shengnan Liu, et al.
Journal of Materials Chemistry B (2021) Vol. 9, Iss. 42, pp. 8809-8822
Closed Access | Times Cited: 7
Showing 7 citing articles:
Assembling Au8 clusters on surfaces of bifunctional nanoimmunomodulators for synergistically enhanced low dose radiotherapy of metastatic tumor
Rui Zhang, Mengchao Jia, Hongying Lv, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Rui Zhang, Mengchao Jia, Hongying Lv, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Prodrug-designed nanocarrier co-delivering chemotherapeutic and vascular disrupting agents with exceptionally high drug loading capacity
Huicong Zhou, Zhaofan Yang, Guan-Yu Jin, et al.
Journal of Controlled Release (2025), pp. 113628-113628
Closed Access
Huicong Zhou, Zhaofan Yang, Guan-Yu Jin, et al.
Journal of Controlled Release (2025), pp. 113628-113628
Closed Access
Nanomedicine Targeting Myeloid‐Derived Suppressor Cells Enhances Anti‐Tumor Immunity
En‐Li Yang, Zhi‐Jun Sun
Advanced Healthcare Materials (2024) Vol. 13, Iss. 9
Closed Access | Times Cited: 3
En‐Li Yang, Zhi‐Jun Sun
Advanced Healthcare Materials (2024) Vol. 13, Iss. 9
Closed Access | Times Cited: 3
Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer
Caroline B. Linde, Yu-Ting Chien, Zhiqian Chen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Caroline B. Linde, Yu-Ting Chien, Zhiqian Chen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Comprehensive review of drug-mediated ICD inhibition of breast cancer: mechanism, status, and prospects
Yang Wang, Rui Yang, Ying Xie, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
Yang Wang, Rui Yang, Ying Xie, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
A Nanotheranostic Agent for Synergistic Antitumor Chemo/Phototherapy Prepared by Paclitaxel-Induced Self-Assembly of PEGylated Human Serum Albumin with Prolonged Circulation
Yijie Liu, Wen-Jia Xu, Xinlei Song, et al.
ACS Omega (2024) Vol. 9, Iss. 52, pp. 51062-51072
Open Access
Yijie Liu, Wen-Jia Xu, Xinlei Song, et al.
ACS Omega (2024) Vol. 9, Iss. 52, pp. 51062-51072
Open Access
Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy
Lu An, Yuhao Guo, Yi Yan, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 6, pp. 108928-108928
Closed Access
Lu An, Yuhao Guo, Yi Yan, et al.
Chinese Chemical Letters (2023) Vol. 35, Iss. 6, pp. 108928-108928
Closed Access
